Japan OKs Roche's Avastin for aggressive brain cancer

Roche has obtained approval from the Japanese Ministry of Health, Labour and Welfare to market Avastin, or bevacizumab, as a treatment for malignant glioma, including newly diagnosed glioblastoma, in combination with radiotherapy and temozolomide, and as a monotherapy for recurrent GBM and certain kinds of high-grade glioma. The approval makes Avastin the first globally approved drug for newly diagnosed glioblastoma.

View Full Article in:

Genetic Engineering & Biotechnology News · Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ